Cortisone acetate
Cortone (cortisone acetate) is a small molecule pharmaceutical. Cortisone acetate was first approved as Cortisone acetate on 1982-01-01. It is used to treat adrenal insufficiency, allergic rhinitis, ankylosing spondylitis, asthma, and atopic dermatitis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Show 7 more
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cortisone acetate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CORTISONE ACETATE | Impax Laboratories | N-009458 DISCN | 1982-01-01 | 1 products |
| CORTONE | Merck & Co | N-007110 DISCN | 1982-01-01 | 2 products |
| CORTONE | Merck & Co | N-007750 DISCN | 1982-01-01 | 1 products, RLD |
| CORTISONE ACETATE | Panray Corporation | N-008284 DISCN | 1982-01-01 | 2 products |
| CORTISONE ACETATE | Pharmacia & Upjohn | N-008126 DISCN | 1982-01-01 | 4 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cortisone acetate | ANDA | 2025-06-06 |
Indications
FDA
EMA
Show 19 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H02: Corticosteroids for systemic use
— H02A: Corticosteroids for systemic use, plain
— H02AB: Glucocorticoids, systemic
— H02AB10: Cortisone
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01B: Antiinflammatory agents, ophthalmologic
— S01BA: Corticosteroid ophthalmologic antiinflammatory agents, plain
— S01BA03: Cortisone
HCPCS
Code | Description |
|---|---|
| J1700 | Injection, hydrocortisone acetate, up to 25 mg |
Clinical
Clinical Trials
195 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 1 | — | 1 | 1 | 2 | 5 |
| Trigger finger disorder | D052582 | — | M65.3 | — | — | — | 1 | 3 | 4 |
| Adrenal insufficiency | D000309 | — | — | — | — | 1 | 1 | 1 | 3 |
| Shoulder pain | D020069 | — | M25.51 | — | 1 | — | 1 | 1 | 3 |
| Nervous system diseases | D009422 | — | G00-G99 | — | 1 | — | 1 | — | 2 |
| Congenital adrenal hyperplasia | D000312 | — | E25.0 | — | 1 | — | 1 | — | 2 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | 1 | 1 | 2 |
| Addison disease | D000224 | — | E27.1 | — | — | — | 1 | 1 | 2 |
| Kidney transplantation | D016030 | — | — | — | — | — | 1 | — | 1 |
| Facial paralysis | D005158 | — | G51.0 | — | — | — | 1 | — | 1 |
Show 13 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 10 | 23 | 14 | — | 1 | 42 |
| Prostatic neoplasms | D011471 | — | C61 | 3 | 23 | 3 | — | — | 27 |
| Burkitt lymphoma | D002051 | — | C83.7 | 7 | 14 | 8 | — | — | 26 |
| Lymphoma | D008223 | — | C85.9 | 10 | 13 | 2 | — | — | 20 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 11 | 12 | 2 | — | — | 19 |
| B-cell lymphoma | D016393 | — | — | 10 | 12 | 1 | — | — | 18 |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | 5 | 9 | 5 | — | — | 15 |
| Leukemia | D007938 | — | C95 | 2 | 7 | 3 | — | — | 10 |
| Lymphoid leukemia | D007945 | — | C91 | 2 | 7 | 3 | — | — | 10 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | 7 | 1 | — | — | 8 |
Show 29 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenocarcinoma | D000230 | — | — | 1 | 15 | — | — | — | 16 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 7 | 9 | — | — | — | 13 |
| Carcinoma | D002277 | — | C80.0 | 1 | 5 | — | — | — | 5 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 4 | 3 | — | — | — | 5 |
| Recurrence | D012008 | — | — | 3 | 3 | — | — | — | 4 |
| Myelodysplastic syndromes | D009190 | — | D46 | 3 | 1 | — | — | — | 3 |
| Syndrome | D013577 | — | — | 1 | 2 | — | — | 1 | 3 |
| Plasmablastic lymphoma | D000069293 | — | C83.3 | 3 | 2 | — | — | — | 3 |
| Large-cell lymphoma immunoblastic | D016400 | — | — | 3 | 2 | — | — | — | 3 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 1 | — | — | 1 | 3 |
Show 66 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 2 | — | — | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | — | — | — | — | 1 |
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | 1 | — | — | — | — | 1 |
| Colitis | D003092 | EFO_0003872 | K52.9 | 1 | — | — | — | — | 1 |
| Deltaretrovirus infections | D006800 | EFO_1001303 | — | 1 | — | — | — | — | 1 |
| Htlv-i infections | D015490 | EFO_0007316 | — | 1 | — | — | — | — | 1 |
| Aids-related lymphoma | D016483 | EFO_1001365 | — | 1 | — | — | — | — | 1 |
| Composite lymphoma | D058617 | — | — | 1 | — | — | — | — | 1 |
| Fanconi anemia | D005199 | Orphanet_84 | D61.03 | 1 | — | — | — | — | 1 |
Show 6 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hip osteoarthritis | D015207 | EFO_1000786 | M16 | — | — | — | — | 3 | 3 |
| Giant cell arteritis | D013700 | EFO_1001209 | M31.6 | — | — | — | — | 2 | 2 |
| Polymyalgia rheumatica | D011111 | EFO_0008518 | M35.3 | — | — | — | — | 2 | 2 |
| Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | — | — | — | — | 2 | 2 |
| Arthralgia | D018771 | — | M25.5 | — | — | — | — | 2 | 2 |
| Rotator cuff injuries | D000070636 | — | M75.1 | — | — | — | — | 2 | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 2 | 2 |
| Acth-secreting pituitary adenoma | D049913 | — | — | — | — | — | — | 1 | 1 |
| Deglutition disorders | D003680 | — | R13.1 | — | — | — | — | 1 | 1 |
| Thyroidectomy | D013965 | — | — | — | — | — | — | 1 | 1 |
Show 38 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cortisone acetate |
| INN | cortisone |
| Description | Cortisone acetate is a corticosteroid hormone. |
| Classification | Small molecule |
| Drug class | Corticosteroid; Glucocorticoid |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C |
Identifiers
| PDB | — |
| CAS-ID | 50-04-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1650 |
| ChEBI ID | 3897 |
| PubChem CID | 5745 |
| DrugBank | DB01380 |
| UNII ID | 883WKN7W8X (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Cortisone acetate
+
Cortisone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
42,950 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use